## CARPETIMYCINS A AND B, NEW $\beta$ -LACTAM ANTIBIOTICS

Sir:

Carpetimycins A and B, two new carbapenem antibiotics related to the thienamycin<sup>1,2)</sup>, olivanic acid derivatives<sup>3~5)</sup> and PS-5<sup>®)</sup> have been found in the culture filtrate of *Streptomyces* sp. KC-6643. The strain was cultured in an Erlenmeyer flask which contained 100 ml of a medium composed of 3.6% starch, 2.2% soybean meal, 1.5% cotton seed oil, 0.62% Na<sub>2</sub>HPO<sub>4</sub>·12H<sub>2</sub>O, 0.1% KH<sub>2</sub>PO<sub>4</sub>, 0.05% MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.001% FeSO<sub>4</sub>·7H<sub>2</sub>O and 0.0005% CoCl<sub>2</sub>·6H<sub>2</sub>O, on a rotary shaker at 29°C for 72 hours. Five hundred ml of the culture broth was inoculated into 100 liters of the same medium in a 200-liter fermentor.

Fermentation was carried out at 29°C under aeration at 100 liters/minute, agitation of 240 rpm and inner pressure of 0.5 kg/cm<sup>2</sup>. The 144-hour cultured broth was filtered with Dicalite (Dicalite Orient Co., Ltd., Japan) as filter aid. The antibiotics in the filtrate (200 liters) were adsorbed on a column of Diaion PA-306 (Mitsubishi Kasei Kogyo Co., Ltd.) and then eluted with 20% NaCl. The active fractions were desalted on a Diaion HP-20 (Mitsubishi Kasei Kogyo Co., Ltd.) column. The active eluate was charged on a column of Amberlite IRA-458. Carpetimycins A and B were eluted with 0.9% and 20% NaCl, respectively. The fraction containing carpetimycin A was subjected to successive column chromatography with QAE-Sephadex A-25, Diaion HP-20 and Sephadex G-10. Lyophilization of active fractions from the last column gave a crude powder of carpetimycin A (230 mg, 200 mcg/mg).

The fraction containing carpetimycin B was extracted with 1 % trioctylmethylammonium chloride in dichloromethane, followed by back extraction with 3% sodium iodide. The sodium iodide extract was subjected to succesive column chromatography using DEAE-Sephadex A-25, Diaion HP-20 and Sephadex G-10. Lyophilization of active fractions from the last column gave a crude powder of carpetimycin B (400 mg, 600 mcg/mg). Further purification of the crude powders was accomplished by HPLC (Bondapak C<sub>18</sub>/ Porasil B, Waters Assoc.) to give pure carpetimycins A (39 mg) and B (210 mg) as the sodium salts.

Carpetimycin A sodium salt is a colorless solid

melting above 145°C with decomposition.  $[\alpha]_D^{24}$ -27° (c 1.7, water). The antibiotic shows UV (H<sub>2</sub>O):  $\lambda_{max}$  240 nm (E<sup>1%</sup><sub>1cm</sub> 369) and 288 nm (E<sup>1%</sup><sub>1cm</sub> 300), IR (KBr): 1770, 1695, 1625 and 1265 cm<sup>-1</sup>, <sup>1</sup>H-NMR (D<sub>2</sub>O):  $\partial$  1.83 (3H s, CH<sub>3</sub>-C-), 1.91 (3H s, CH<sub>3</sub>-C-), 2.65 (3H s, CH<sub>3</sub>-CO-), 3.54 (1H dd, J=11, 17 Hz), 4.32 (1H, d, J= 5.5 Hz), 4.43 (1H dd, J=8, 17 Hz), 4.98 (1H m), 6.92 (1H d, J=14 Hz), 8.10 (1H d, J=14 Hz). FD Mass: 357 (MH<sup>+</sup> of methylester). Molecular ion peak of mass spectrum, the <sup>13</sup>C-NMR data and the analytical data for carpetimycin A agreed with the molecular formula C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>6</sub>S.

Carpetimycin B disodium salt is a colorless solid melting above 130°C with decomposition.  $[\alpha]_{2^4}^{2^4}-145^\circ$  (*c* 1, water). The antibiotic shows UV (H<sub>2</sub>O):  $\lambda_{max}$  240 nm (E<sub>1em</sub><sup>1%</sup> 357) and 285 nm (E<sub>1em</sub><sup>1%</sup> 305), IR (KBr): 1770, 1695, 1625, 1270~ 1220 and 1050 cm<sup>-1</sup>, <sup>1</sup>H-NMR (D<sub>2</sub>O):  $\delta$  2.15 (3H s, CH<sub>3</sub>-C-), 2.23 (3H s, CH<sub>3</sub>-C-), 2.65 (3H s, CH<sub>3</sub>-CO-), 3.62 (1H dd, J=11, 18 Hz), 4.42

Table 1. Antibacterial activity of carpetimycins A and B.

Organisms	MIC (µg/ml)	
	Carpeti- mycin A	Carpeti- mycin B
Staphylococcus aureus 209P JC-1	0.39	6.25
Bacillus subtilis ATCC 6633	0.2	6.25
Escherichia coli NIHJ JC-2	0.05	1.56
Escherichia coli ML 1410 R EC-1*	0.2	3.13
Klebsiella pneumoniae PCI-602	0.2	6.25
Kiebsiella pneumoniae 25*	0.78	6.25
Proteus vulgaris IID 874	0.39	12.5
Proteus vulgaris 69*	0.78	25
Proteus morganii IFO 3168	0.39	12.5
Proteus morganii 41*	1.56	25
Citrobacter freundii 24*	1.56	12.5
Enterobacter cloacae IID 977	0.78	6.25
Enterobacter cloacae 3*	3.13	12.5
Serratia marcescens NHL	0.2	6.25
Serratia marcescens 4*	3.13	25
Pseudomonas aeruginosa NCTC 10490	6.25	25

Tests were conducted in Brain Heart Infusion agar inoculated with  $10^8$  cells per ml.

β-lactamase producing organism

Table 2.  $\beta$ -Lactamase inhibitory activity of carpetimycins A and B.

	I <sub>50</sub> (ng/ml)	
	Escherichia coli ML 1410 R EC-1 (PCase)	Proteus vulgaris 69 (CSase)
Substrate	PCG	CER
Carpetimycin A	0.64	0.52
Carpetimycin B	0.21	0.74


Inhibitor was incubated with enzyme at  $30^{\circ}$ C for 5 minutes prior to addition of substrate ( $100 \, \mu$ M final concentration). The hydrolysis of PCG was assayed by a modification of the NOVIK micro-iodometric method and that of CER was measured by direct UV spectrophotometry.

(1H dd, J=8, 18 Hz), 4.50 (1H d, J=5.5 Hz), 5.04 (1H m), 6.95 (1H d, J=14 Hz), 8.13 (1H d, J=14 Hz). The <sup>18</sup>C-NMR data and the analytical data for carpetimycin B agreed with the molecular formula  $C_{14}H_{18}N_2O_9S_2$ . By high-voltage paper electrophoresis with 3,000 V for 20 minutes in 1/30 M phosphate buffer (pH 8.0), carpetimycins A and B move to the anode with *Rm* (relative mobility to penicillin N) 1.0 and 2.4, respectively. Carpetimycins A and B can be separated by thinlayer chromatography on cellulose  $F_{254}$  (E. Merck, Art 5574) developed with 1-butanol - 2propanol - water (7: 7: 6) (Rf 0.60 for A and 0.40 for B).

The antibiotics are more stable than olivanic acid derivatives<sup>7)</sup>. In MCILVAINS sodium phosphate-citric acid buffer (pH 7.0) at  $25^{\circ}$ C the half-lives of carpetimycins A and B are 187 and 170 hours, respectively.

Carpetimycins A and B have strong activity against Gram-positive and Gram-negative bac-

Fig. 1. Chemical structures of carpetimycins A and B.



teria, including  $\beta$ -lactamase producing strains, as shown in Table 1. The activity of carpetimycin A is  $8 \sim 32$  times greater than that of B. They also show inhibitory activity against  $\beta$ lactamase, as shown in Table 2.

The structures of carpetimycins A and B were elucidated by their spectral data and conversion of carpetimycin B into A. The final structure determination including stereochemistry was accomplished by X-ray crystallographic analysis\* of the carpetimycin A *p*-bromobenzyl ester as shown in Fig. 1.

The structure elucidation of carpetimycins A and B will be described in due course.

## Acknowledgements

The authors wish to thank Drs. H. UMEZAWA and K. MAEDA, Institute of Microbial Chemistry for a gift of MC696-SY2-A, their helpful advice and encouragements through this work. Thanks are also due to Prof. T. GOTO, Nagoya University, for the measurement of the FD mass spectrum. Thanks are also due to Dr. J. BIRNBAUM, Merck Sharp & Dohme, for a gift of thienamycin and to Dr. T. ISHIKURA, Sanraku-Ocean Co., Ltd., for a gift of PS-5.

> Masahito Nakayama Akio Iwasaki Shigeru Kimura Toshimi Mizoguchi Sohei Tanabe Akira Murakami Isamu Watanabe Masao Okuchi Hisakatsu Itoh Yushi Saino Fujio Kobayashi Toshihito Mori

Tokyo Research Laboratories Kowa Co., Ltd., Higashimurayama, Tokyo 189, Japan

(Received September 13, 1980)

## References

 Alberg-Schönberg, G.; B. H. Arison, O. D. Hensens, J. Hirshfield, K. Hoogsteen, E. A. Kaczka, R. E. Rhodes, J. S. Kahan, F. M. Kahan, R. W. Ratcliffe, E. Walton, L. J.

\* The structure determination by X-ray crystallography was carried out in cooperation with Prof. T. KAWASAKI and others of Kyushu University. RUSWINKLE, R. B. MORIN & B. G. CHRISTENSEN: Structure and absolute configuration of thienamycin. J. Am. Chem. Soc. 100: 6491~6499, 1978

- 2) CASSIDY, P. J.; E. O. STAPLEY, R. GOEGELMAN, T. W. MILLER, B. ARISON, G. ALBERS-SCHÖN-BERG, S. B. ZIMMERMAN & J. BIRNBAUM: Epithienamycins. Isolation and identification of epithienamycins. Presented at the 17th Intersci. Conf. Antimicr. Agents and Chemoth., No. 80, New York, N. Y., Oct. 12~14, 1977
- BROWN, A. G.; D. F. CORBETT, A. J. EGLINGTON & T. T. HOWARTH: Structures of olivanic acid derivatives MM 4550 and MM 13902, two new fused β-lactams isolated from *Streptomyces olivaceus*. J. C. S., Chem. Comm. 1977: 523~ 525, 1977
- CORBETT, D. F.; J. EGLINGTON & T. T. HOWRTH: Structure elucidation of MM 17880, a new fused β-lactam antibiotic isolated from *Streptomyces* olivaceus; a mild β-lactam degradation reaction.

J. Chem. Soc., Chem. Comm. 1977: 953~954, 1977

- 5) BROWN, A. G.; D. F. CORBETT, A. J. EGLINGTON & T. T. HOWARTH: Structure of olivanic acid derivatives MM 22380, MM 22381, MM 22382 and MM 22383; Four new antibiotics isolated from *Streptomyces olivaceus*. J. Antibiotics 32: 961~963, 1979
- 6) YAMAMOTO, K.; T. YOSHIOKA, Y. KATO, N. SHIBAMOTO, K. OKAMURA, Y. SHIMAUCHI & T. ISHIKURA: Structure and stereochemistry of antibiotic PS-5. J. Antibiotics 33: 796~803, 1980
- Hood, J. D.; S. J. Box & M. S. VERRALL: Olivanic acids, a family of β-lactam antibiotics with β-lactamase inhibitory properties produced by *Streptomyces* species. II. Isolation and characterisation of the olivanic acids MM 4550, MM 13902 and MM 17880 from *Streptomyces olivaceus*. J. Antibiotics 32: 295~304, 1979